TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. acute myeloid leukemia (AML) in CR1 (complete remission 1) or CR2 (complete remission 2) phase regardless of cytogenetics;~2. CML CP(chronic myelogenous leukemia , chronic phase); NHL (non-Hodgkin's lymphoma )~3. MDS-RAEB(myelodysplastic syndrome -refractory anemia with excess blasts ).~4. All patients should aged 40 to 70 years~5. Have matched sibling donor.~6. Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases .~Exclusion Criteria:~1. Patients aged less than 40 years old ;~2. Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or cardiac diseases;~3. AML patients with t (15;17);

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ATG combined regimen (Type: EXPERIMENTAL): ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
- no-ATG (Type: ACTIVE_COMPARATOR): regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of persistent/chronic ITP for at least 3 months~* Average platelet count\< 30,000/µL (and none \> 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts~Exclusion Criteria:~* Clinical diagnosis of autoimmune hemolytic anemia~* Uncontrolled or poorly controlled hypertension~* History of coagulopathy including prothrombotic conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib Disodium (Type: EXPERIMENTAL): Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
- Placebo (Type: OTHER): Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents between and including 11-17 years of age, who provide written informed consent~Exclusion Criteria:~* Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: None

Study Arms:
- MenACWY-CRM(Ad+) (Type: EXPERIMENTAL): Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
- MenACWY-CRM(Ad-) (Type: EXPERIMENTAL): Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
- MenACWY- PS (Type: ACTIVE_COMPARATOR): Subjects received one single dose of the polysaccharide vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Letrozole and Clomid in Women With Infertility and PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing to comply with all study procedures and be available for the duration of the study~2. Diagnosis of infertility: Inability of couple to achieve successful pregnancy after 12 months of regular timed unprotected intercourse in women less than 35 years of age; and after 6 months of regular intercourse without use of contraception in women 35 years and older~3. Diagnosis of polycystic ovary syndrome based on Revised Rotterdam criteria~4. Ability to have regular intercourse during the ovulation induction phase of the study~5. Normal sperm concentration of 15 million/mL and with normal motility of \> 40% according to World Health Organization cutoff points, in at least one ejaculate during the previous year~Exclusion Criteria:~1. Current pregnancy~2. Current use of hormonal contraception; use of any type of combined contraceptive or oral progestins within the past month; or use of hormonal implants or depo progestins within the past 3 months~3. Other known cause of infertility: endometriosis, tubal factor, uterine abnormalities~4. Uncorrected thyroid disease~5. Untreated hyperprolactinemia.~6. Medical conditions in which avoiding pregnancy is recommended until under improved control: poorly controlled Type 1 or Type 2 diabetes, poorly controlled hypertension~7. Contraindications to clomiphene citrate: hypersensitivity to CC or any of its components, history of liver disease or known liver disease, unknown cause of abnormal uterine bleeding, or intracranial lesion~8. Contraindications to letrozole: hypersensitivity to letrozole or any of its components.~9. Use of medications known to affect reproductive function or metabolism or that are an absolute contraindication during pregnancy within the past month.~10. If patients are suspected based on clinical findings for other etiologies that mimic PCOS, work up must be completed to exclude other etiologies prior to enrollment (i.e. Cushing's syndrome, androgen-secreting tumor).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: ACTIVE_COMPARATOR): Letrozole 2.5 mg orally for 5 days on cycle days 3-7
- Letrozole + Clomiphene (Type: EXPERIMENTAL): Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females without child bearing potential aged 21-80 years~* Fasting low-density lipoprotein (LDL) level \> 120mg/dL.~* Either known to be diabetic or have at least 3 components of metabolic syndrome that are defined below:~  * Hypertension defined as blood pressure (BP) \> 140 systolic or \> 90 mmHg diastolic, or stable medical therapy for documented hypertension;~ * Fasting glucose \> 110 mg/dL;~ * Waist \> 40 inches in males, and \> 35 inches in females;~ * Triglycerides \> 150mg/dL; or~ * High-density lipoprotein (HDL) cholesterol \< 40 mg/dL in males and \< 50 mg/dL in females.~* Able to provide written informed consent~* Non-smoker~Exclusion Criteria:~* On any oral antioxidants or lipid lowering medications in the previous 8 weeks~* Age \< 21 or \> 80 years~* Premenopausal females with potential for pregnancy~* LDL cholesterol level \< 120 mg/dl~* Initiation or change in dose of any concomitant medical therapy within 2 months before the study~* Uncontrolled hypertension with BP \> 180 mmHg systolic and \> 120 mmHg diastolic~* Current smoker~* Previous intolerance or allergy to statins~* Acute infection in previous 4 weeks~* History of substance abuse~* Uninterpretable Brachial Artery Reactivity Study~* Current neoplasm~* Chronic renal failure (creatinine \> 2.5 mg/dL) or liver failure (liver enzymes \> 2X normal)~* Acute coronary syndrome, heart failure, cerebrovascular accident (CVA), or coronary intervention within 3 months~* Known aortic stenosis, hypertrophic cardiomyopathy, or symptomatic heart failure.~* Inability to give informed consent~* Inability to return to Emory for follow-up

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin 10MG (Type: EXPERIMENTAL): None
- Pravastatin 80mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signs and symptoms of VL including:~   * History of intermittent fever for at least two weeks~  * History of weight loss and/or decrease in appetite~  * Enlarged spleen~2. VL serologically confirmed using the rK39 test:~3. Willingness / ability to understand and provide informed consent prior to participation in this study:~4. Age ≥ five years and ≤ 55 years, and weighing at least five kg~5. Adequately hydrated as assessed by clinical criteria and able to maintain adequate hydration on an outpatient basis through oral intake of fluids~6. Clinically stable and appropriate for treatment with PMIM as an outpatient, if possible (subjects may be hospitalized to receive 21-day dosing at the discretion of the investigator)~7. Living in the VL-endemic areas in Bangladesh~Exclusion Criteria:~1. Active tuberculosis or taking anti-tuberculosis medications~2. Previous treatment with Paromomycin IM Injection (PMIM)~3. Clinically significant severe anemia as determined by the investigator~4. Clinically significant renal or hepatic dysfunction as determined by the investigator, or history of clinically significant renal or hepatic dysfunction~5. History of Hepatitis B or C; or known HIV positive~6. History of hearing loss~7. Other serious illness or medical condition that, in the opinion of the doctor, would interfere with the patient's ability to receive PMIM treatment or comply with the study procedures, or that could obscure toxicity of or response to PMIM~8. Major surgery within 30 days prior to first dose of PMIM~9. History of hypersensitivity to aminoglycosides or to any of the components of PMIM, including sulfite~10. Any history of VL or treatment of VL at any time~11. Patients who have received any investigational (unlicensed) drug within the last six months~12. Concomitant use of other aminoglycosides (e.g., gentamicin, tobramycin, amikacin), nephrotoxic and ototoxic drugs, or immunosuppressive drugs~13. Proteinuria (results \> 1+ ) on urine dipstick analysis at screening visit and/or~14. Serum creatinine above the upper limit of normal (ie, serum creatinine \>1.1 mg/dl in males and \>0.9 mg/dl in females~15. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DA-3002 in Short Children Borns SGA.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological Age ≥ 4~* Before the adolescence, Tuner stage I (breast)~* Height \<3rd percentile for age~* Normal thyroid function~Exclusion Criteria:~* Growth hormone was administered for 12 months or longer in the past~* Treated with estrogen or adrenal androgens for 12 months or longer in the past~* Malignancy, CNS Trauma, Psychiatric Disorder~* endocrine and/or metabolic disorders~* growth failure caused by other disorders

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- DA-3002 (Type: EXPERIMENTAL): 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
- Genotropin® (Type: ACTIVE_COMPARATOR): 1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
- Non-treatment control group (Type: OTHER): After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should complete the week 16 assessments in the double-blind study (TA-7284-11)~Exclusion Criteria:~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with serious renal or hepatic disease~* Patients who are the excessive alcohol addicts~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋insulin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Engaging Immigrants in Preventive Parenting Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The sample will consist of Filipino parents and grandparents of children/grandchildren between ages 6-12 years old. Inclusion criteria include:~  1. the parent or grandparent has at least one child between 6 to 12 years of age~ 2. the participating parent/grandparent is Filipino~ 3. At least one parent/grandparent is willing to complete pre and post surveys and watch a brief video~ 4. the parent/grandparent is age 18 or older~ 5. English fluency~Exclusion Criteria:~1. Younger than 18 years of age~2. Does not speak English~3. Target child has a developmental disability such as Trisomy 21 or autism~4. Parent or grandparent plans to move out of the area within the next nine months

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
- Control Arm (Type: OTHER): Usual care video publicly available describing the evidence-based parenting intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Letter of consent and release signed by each patient~* Body mass index: 25-34.99 kg/m2~* Body weight without variations above or under 5% during the three months prior to the study~* Diagnostic of metabolic syndrome according to the modified International Diabetes Federation definition: Central obesity (defined as waist circumference ≥ 80 cm in women and ≥ 90 cm in men)~Plus any two of the following four factors:~* Triglycerides: 150-499 mg/dL.~* High density lipoprotein: Woman \< 50 mg/dL, man \< 40 mg/dL.~* Blood pressure systolic:130-139 mmHg and/or Blood pressure diastolic: 85-89 mmHg~* Fasting glucose: 100-125 mg/dL~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Previous pharmacological treatment for components of metabolic syndrome~* Mental or physical illness interfering with the study~* Thyroid or cardiovascular disease~* Pregnant or suspected pregnant women~* Woman breastfeeding~* Index of body mass: ≥ 35 kg/m2~* Treatments known to affect metabolism of glucose, fats and affecting arterial tension~* Patients with hepatic or renal diseases background~* Patients diagnosed with kidneys disease~* Calcined magnesium intolerance~* Gymnema Sylvestre intolerance

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
- Gymnema Sylvestre (Type: EXPERIMENTAL): 600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daratumumab in Treatment of PGNMID and C3 GN

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age~* Renal biopsy read at Mayo Clinic confirming the diagnosis of PGNMID or C3 GN~* In cases of C3GN serum electrophoresis with immunofixation should confirm presence of monoclonal gammopathy~* Proteinuria ≥ 1000 mg over 24 hours~* eGFR ≥ 20 mL/min/SA~* Subjects able and willing to give informed consent~Exclusion Criteria:~* Pregnancy~* Hepatitis B or C, HIV~* Multiple myeloma~* Anemia with Hgb \< 8.5 g/dL~* Thrombocytopenia with platelet count \< 100,000~* Leukopenia with WBC \< 3.5~* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication~* Unable to provide consent~* Patients receiving therapy with oral prednisone or glucocorticoid equivalent in the last 6 weeks~* Patients who had received immunosuppressive therapy including cyclophosphamide, MMF, cyclosporine, tacrolimus or azathioprine in the last 3 months~* Patients who received rituximab previously with CD20 count of zero at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab (Type: EXPERIMENTAL): Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment with onabotulinumtoxinA according to the decision of the physician for spasticity~* Willingness to complete study questionnaires and answer study questions by phone or internet~Exclusion Criteria:~* Concurrent participation in a clinical trial for spasticity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- onabotulinumtoxinA (Type: None): onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing Mestinon and Exercise in Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have Fibromyalgia~Exclusion Criteria:~* Subjects will be excluded if they have a history of rheumatic disease or other disorder that may compromise ability to safely complete study protocol, be pregnant, nursing, or currently involved in unresolved litigation.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete